rs144189837
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 4P and 4B. PM1PP2PP3BS2
The NM_000138.5(FBN1):āc.7379A>Gā(p.Lys2460Arg) variant causes a missense change. The variant allele was found at a frequency of 0.000106 in 1,614,072 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.000072 ( 0 hom., cov: 33)
Exomes š: 0.00011 ( 0 hom. )
Consequence
FBN1
NM_000138.5 missense
NM_000138.5 missense
Scores
5
6
6
Clinical Significance
Conservation
PhyloP100: 6.26
Genes affected
FBN1 (HGNC:3603): (fibrillin 1) This gene encodes a member of the fibrillin family of proteins. The encoded preproprotein is proteolytically processed to generate two proteins including the extracellular matrix component fibrillin-1 and the protein hormone asprosin. Fibrillin-1 is an extracellular matrix glycoprotein that serves as a structural component of calcium-binding microfibrils. These microfibrils provide force-bearing structural support in elastic and nonelastic connective tissue throughout the body. Asprosin, secreted by white adipose tissue, has been shown to regulate glucose homeostasis. Mutations in this gene are associated with Marfan syndrome and the related MASS phenotype, as well as ectopia lentis syndrome, Weill-Marchesani syndrome, Shprintzen-Goldberg syndrome and neonatal progeroid syndrome. [provided by RefSeq, Apr 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM1
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 1 benign, 8 uncertain in NM_000138.5
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), FBN1. . Gene score misZ 5.0644 (greater than the threshold 3.09). Trascript score misZ 8.1787 (greater than threshold 3.09). GenCC has associacion of gene with MASS syndrome, Weill-Marchesani syndrome, geleophysic dysplasia, Shprintzen-Goldberg syndrome, Acromicric dysplasia, familial thoracic aortic aneurysm and aortic dissection, progeroid and marfanoid aspect-lipodystrophy syndrome, ectopia lentis 1, isolated, autosomal dominant, Marfan syndrome, Weill-Marchesani syndrome 2, dominant, isolated ectopia lentis, neonatal Marfan syndrome, stiff skin syndrome.
PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
BS2
High AC in GnomAd4 at 11 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.7379A>G | p.Lys2460Arg | missense_variant | 60/66 | ENST00000316623.10 | |
FBN1 | NM_001406716.1 | c.7379A>G | p.Lys2460Arg | missense_variant | 59/65 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.7379A>G | p.Lys2460Arg | missense_variant | 60/66 | 1 | NM_000138.5 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152228Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
11
AN:
152228
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000637 AC: 16AN: 251300Hom.: 0 AF XY: 0.0000810 AC XY: 11AN XY: 135820
GnomAD3 exomes
AF:
AC:
16
AN:
251300
Hom.:
AF XY:
AC XY:
11
AN XY:
135820
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000109 AC: 160AN: 1461844Hom.: 0 Cov.: 32 AF XY: 0.000100 AC XY: 73AN XY: 727226
GnomAD4 exome
AF:
AC:
160
AN:
1461844
Hom.:
Cov.:
32
AF XY:
AC XY:
73
AN XY:
727226
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152228Hom.: 0 Cov.: 33 AF XY: 0.0000941 AC XY: 7AN XY: 74378
GnomAD4 genome
AF:
AC:
11
AN:
152228
Hom.:
Cov.:
33
AF XY:
AC XY:
7
AN XY:
74378
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
2
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
9
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:15
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:7
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 22, 2024 | Has been reported in association with Marfan syndrome in published literature, and frequently referred to as a variant of uncertain significance (PMID: 17627385, 21895641, 24941995, 25644172, 29907982); Reported in cis with FBN1 p.(N542S) in a patient with bicuspid aortic valve, TAAD, and additional connective tissue features who also harbored variants in TGFBR3, NOTCH1, and LTBP1; the FBN1 variants segregated with systemic connective tissue features in his mother, and the TGFBR3 variant segregated with aortic root dilation in his father and siblings (PMID: 30255099); At the protein level, in silico analysis indicates that this missense variant does not alter protein structure/function; At the mRNA level, in silico analysis supports a deleterious effect on splicing; Although located in a calcium-binding EGF-like domain of the FBN1 gene, it does not affect a cysteine residue within this domain; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (PMID: 12938084); This variant is associated with the following publications: (PMID: 24055113, 25812041, 25637381, 24941995, 32123317, 25644172, 21895641, 29907982, 17627385, 34663891, 30255099, 12938084) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Mar 16, 2021 | No ACMG evidence could be applied applied - |
Uncertain significance, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Jan 26, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Marfan syndrome Uncertain:3
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 11, 2024 | This missense variant replaces lysine with arginine at codon 2460 of the FBN1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may impact RNA splicing. However, an RNA study showed no abnormal splicing (PMID: 32123317). This variant has been reported in one individual affected with Marfan syndrome or Marfan-like phenotype (PMID: 17627385, 21895641) and in an individual affected with bicuspid aortic valve, a common congenital heart defect with increased prevalence of aortic dilatation/dissection (PMID: 30255099). This variant was also reported in an individual with aortic dissection and suspected hereditary thoracic aortic disease (PMID: 29907982) along with another individual who was affected with non-syndromic heritable thoracic aortic disorder (PMID: 25644172). This variant has also been identified in 20/282708 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Center for Medical Genetics Ghent, University of Ghent | Nov 07, 2017 | - - |
Familial thoracic aortic aneurysm and aortic dissection Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 20, 2023 | This missense variant replaces lysine with arginine at codon 2460 of the FBN1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may impact RNA splicing. However, an RNA study showed no abnormal splicing (PMID: 32123317). This variant has been reported in one individual affected with Marfan syndrome or Marfan-like phenotype (PMID: 17627385, 21895641) and in an individual affected with bicuspid aortic valve, a common congenital heart defect with increased prevalence of aortic dilatation/dissection (PMID: 30255099). This variant was also reported in an individual with aortic dissection and suspected hereditary thoracic aortic disease (PMID: 29907982) along with another individual who was affected with non-syndromic heritable thoracic aortic disorder (PMID: 25644172). This variant has also been identified in 20/282708 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 26, 2022 | The p.K2460R variant (also known as c.7379A>G), located in coding exon 59 of the FBN1 gene, results from an A to G substitution at nucleotide position 7379. The lysine at codon 2460 is replaced by arginine, an amino acid with highly similar properties. This alteration has been reported in individuals from cohorts with Marfan syndrome or Marfan-like features; however, details were limited (Campens L et al. Orphanet J Rare Dis, 2015 Feb;10:9; Howarth R et al. Genet. Test., 2007;11:146-52). This variant was also detected in probands with bicuspid aortic valve, aortic dissection/dilation, and systemic features; however, other variants were also detected (Overwater E et al. Hum Mutat. 2018 09;39(9):1173-1192; Sticchi E et al. Biomed Res Int. 2018 Sep;2018:8386123). This alteration has also been seen in exome cohorts, but cardiovascular history was not provided (Dorschner MO et al. Am. J. Hum. Genet., 2013 Oct;93:631-40; Amendola LM et al. Genome Res., 2015 Mar;25:305-15). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 26, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Reported in 1 Marfan proband, 4/5 papers in HGMD classify as VUS due to presence in ESP. ClinVar: 2 VUS - |
FBN1-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 16, 2024 | The FBN1 c.7379A>G variant is predicted to result in the amino acid substitution p.Lys2460Arg. This variant was reported in multiple individuals with Marfan syndrome or related aortopathies (Howarth et al. 2007. PubMed ID: 17627385; Robinson et al. 2012. PubMed ID: 21895641; Campens et al. 2015. PubMed ID: 25644172; Growth et al. 2016. PubMed ID: 25812041). However, this variant was also found to co-occur with other rare variants in genes associated with Marfan syndrome phenotypes (Table S1, Overwater et al. 2018. PubMed ID: 29907982; Sticchi et al. 2018. PubMed ID: 30255099). This variant is reported in 0.015% of alleles in individuals of European (Non-Finnish) descent in gnomAD, which is more common than expected for disease-causing variant. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 2460 of the FBN1 protein (p.Lys2460Arg). This variant is present in population databases (rs144189837, gnomAD 0.01%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with clinical features of Marfan syndrome and thoracic aortic disorders (PMID: 17627385, 21895641, 25644172, 29907982, 30255099). ClinVar contains an entry for this variant (Variation ID: 161239). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on FBN1 protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
MutationTaster
Benign
D
PrimateAI
Pathogenic
T
PROVEAN
Benign
N
REVEL
Pathogenic
Sift
Benign
T
Sift4G
Benign
T
Vest4
MVP
MPC
ClinPred
T
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: -1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at